Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma.

Authors

Andrew B Katims
Peter A Reisz MD, Lehigh Valley Health NetworkFollow
Lucas Nogueira
Hong Truong
Andrew T Lenis
Eugene J Pietzak
Kwanghee Kim
Jonathan A Coleman

Publication/Presentation Date

11-4-2022

Abstract

This review describes the current landscape of targeted therapies in urothelial carcinoma. The standard of care for advanced urothelial carcinoma patients remains platinum-based combination chemotherapy followed by immunotherapy. However, median overall survival for these patients is stilland, subsequently, the development of therapies targeting specific molecular pathways implicated in carcinogenesis such as FGFR inhibition, Nectin-4, Trop-2, and HER2 targeting. As these therapies are demonstrated to be effective in the second-line setting, they will be advanced in the treatment paradigm to localized and even non-muscle invasive disease.

Volume

14

Issue

21

ISSN

2072-6694

Published In/Presented At

Katims, A. B., Reisz, P. A., Nogueira, L., Truong, H., Lenis, A. T., Pietzak, E. J., Kim, K., & Coleman, J. A. (2022). Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma. Cancers, 14(21), 5431. https://doi.org/10.3390/cancers14215431

Disciplines

Medicine and Health Sciences

PubMedID

36358849

Department(s)

Department of Medicine

Document Type

Article